As agricultural biotechnology becomes increasingly commercialised, numerous constraints limit adoption by developing-country producers. These include technology access, impacts on farmers' yields and profits, privatisation of research and intellectual property, biosafety regulatory frameworks, and trade-related market restrictions. This essay analyses development of the genetically modified papaya and its commercialisation in Hawaii as a response to a virulent plant disease, papaya ringspot virus. Results of a survey of Hawaiian papaya growers suggest that the unprecedentedly rapid adoption of GM papaya is due to this technology's having addressed many of these key constraints facing growers. The implications for developing-country adoption of GM varieties are explored.
Download Info
To download:
If you experience problems downloading a file, check if you have the
proper application to
view it first. Information about this may be contained
in the File-Format links below. In case of further problems read
the IDEAS help
file. Note that these files are not on the IDEAS
site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.